About 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of Novo Nordisk's weight-loss drug Wegovy, a study published by Kaiser Family Foundation (KFF) showed on Wednesday. Wegovy was approved by the U.S. health regulator last month for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
Travelers often spend more than they need to for airfare, experts say. Here's what to know about paying for add-ons like your seat assignment.
The other three locations are in Grovetown, inside Evans Fitness Club and across from Regal Augusta Exchange.